Moderna-Merck melanoma vaccine cuts recurrence risk 42% in full trial data
Full phase 3 data show Moderna and Merck's personalized mRNA shot cut melanoma relapse risk 42%, but survival data are immature.
Objective Facts
Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, given with Merck's Keytruda after surgery, lowered the risk of melanoma recurrence or death by 42% compared with Keytruda alone in the phase 3 INTerpath-001 trial, according to data presented by Georgina Long at the ESMO Congress in Madrid on October 24, 2026. The trial enrolled 1,137 patients with stage IIB to IV melanoma; at two years, 82.2% of the vaccine group and 70.0% of the control group were alive without recurrence, CancerNetwork reported. Overall survival was not significantly different yet, with a median follow-up of 24.6 months. The data came out two days early after a leak, and Moderna's stock fell sharply as investors weighed results that BioPharma Dive said landed at the low end of Wall Street's expectations.
Deep Dive
Moderna and Merck first said in August that INTerpath-001 met its main goal, and AJMC reported then that it was the first positive late-stage result for an mRNA cancer treatment. Each dose is built from a patient's own tumor: the tumor is sequenced and up to 34 tumor-specific targets are encoded in mRNA, according to AJMC. The full numbers arrived in Madrid. CancerNetwork reported a hazard ratio of 0.58 for recurrence-free survival, with the benefit appearing after about six months (hazard ratio 0.42 beyond that point, 0.99 before it). Fever and injection site pain were far more common with the vaccine, but serious treatment-related side effects were similar in both arms, and no deaths were tied to intismeran. The results drew two very different readings. Clinicians welcomed them: Long said more time free of melanoma is a meaningful benefit in its own right, per News-Medical, and Eva Munoz Couselo of Vall d'Hebron Institute of Oncology in Barcelona called the findings a major breakthrough while asking for longer follow-up, according to Science Media Centre Spain. Investors focused on the gaps. BioPharma Dive reported that the 38% cut in distant spread was smaller than the earlier phase 2 study suggested, and RBC Capital Markets analyst Trung Huynh wrote that commercial success is far less certain than approval. William Blair's Myles Minter described a sell-the-news reaction, while TD Cowen's Tyler Van Buren said the data cleared the bar for a practice-changing result. STAT reported that Moderna had more than tripled since August before the drop, which helps explain the size of the selloff. ESMO's James Larkin also stressed, per News-Medical, that this is a treatment for people who already have cancer, not a shot that prevents cancer in healthy people. The main open question is survival. Overall survival data are immature and did not meet the prespecified threshold, CancerNetwork reported, so later readouts will show whether fewer relapses mean longer lives. Regulators are next: the companies are in talks with agencies, and the paper is headed to The New England Journal of Medicine. Manufacturing a custom product for each patient is another hurdle; Marisol Soengas of Spain's CNIO said the challenge is scaling that personalization, according to Science Media Centre Spain, and 17.3% of screened patients were excluded for inadequate tumor samples, CancerNetwork reported. The result also lands while federal health officials are cool on mRNA: Newsweek reported that HHS under Robert F. Kennedy Jr. moved in 2025 to wind down 22 mRNA vaccine projects for respiratory infections, a decision HHS said did not cover other uses.